Analyst Rating Update on Illumina (ILMN)

Illumina (NASDAQ:ILMN) : Zacks Investment Research ranks Illumina (NASDAQ:ILMN) as 4, which is a Sell recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 11 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 17 research analysts is 2.35, which indicates as a Buy.

Illumina (NASDAQ:ILMN) : The consensus price target for Illumina (NASDAQ:ILMN) is $158 for the short term with a standard deviation of $27.17. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $235, however, the pessimist price target for the company is $125.

Company shares have received an average consensus rating of Hold for the current week Also, CL King initiates coverage on Illumina (NASDAQ:ILMN). CL King has a Buy rating on the shares. The rating by the firm was issued on June 22, 2016.

Illumina (NASDAQ:ILMN): On Tuesdays trading session , Opening price of the stock was $136.41 with an intraday high of $138.9. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $133.58. However, the stock managed to close at $135.01, a loss of 0.35% for the day. On the previous day, the stock had closed at $135.48. The total traded volume of the day was 1,168,377 shares.

In an insider trading activity, The Securities and Exchange Commission has divulged that Bowman A Blaine, director of Illumina Inc, had unloaded 5,000 shares at an average price of $135.17 in a transaction dated on June 16, 2016. The total value of the transaction was worth $675,850.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.